tbuckley/cabot-search huggingface dataset:
Incorrect Dosage in Table
Journal: JAMA (1982)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Reply to J. Mehta
Authors: Philippe Armand, Haesook T. Kim, Corey S. Cutler, Vincent T. Ho, John Koreth, Edwin P. Alyea, Ann S. LaCasce, Eric D. Jacobsen, David C. Fisher, Jennifer R. Brown, George P. Canellos, Arnold S. Freedman, Robert J. Soiffer, Joseph H. Antin
Journal: Journal of Clinical Oncology (2009)
On Agitation
Authors: Ruth McCann
Journal: Annals of Internal Medicine (2020)

On Being a Doctor17 March 2020On AgitationRuth McCann, MDRuth McCann, MDColumbia University Medical Center and New York State Psychiatric Institute, New York, New York (R.M.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/M19-2455 Audio Reading - “On Agitation” Audio. Michael A. Lacombe, MD, Annals Associate Editor, reads “On Agitation” by Ruth McCann, MD Your browser does not support the audio element. Audio player progress bar Step backward in current audio track Play current audio trackPause current audio track Step forward in current audio track Mute current audio trackUnmute current audio track 00:00/ SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Being afraid of a patient can feel like the worst kind of betrayal. My psychiatry training partly involves working with patients who are feeling and acting out of control. I have struggled to know what to do with the emotions I have in those situations. How dare I feel frightened of, angry toward, or overwhelmed by a person whom I've promised to help?In the psychiatric emergency room and inpatient units—where most patients are in the throes of a mood or psychotic episode—agitation is prevalent, and its forms are manifold. Among the scenarios I've encountered are a man punching another ... Author, Article, and Disclosure InformationAffiliations: Columbia University Medical Center and New York State Psychiatric Institute, New York, New York (R.M.)Corresponding Author: Ruth McCann, MD, New York State Psychiatric Institute, 1051 Riverside Drive, Box 85, New York, NY 10032; e-mail, ruth.[email protected]columbia.edu. PreviousarticleNextarticle Advertisement Audio Reading - “On Agitation” Audio. Michael A. Lacombe, MD, Annals Associate Editor, reads “On Agitation” by Ruth McCann, MD Your browser does not support the audio element. Audio player progress bar Step backward in current audio track Play current audio trackPause current audio track Step forward in current audio track Mute current audio trackUnmute current audio track 00:00/ FiguresReferencesRelatedDetails Metrics 17 March 2020Volume 172, Issue 6Page: 431-432KeywordsEmotionsHealth care providersInpatientsPharmacologyPregnancyRacial and ethnic issuesResidencySleepSurgerySweat ePublished: 17 March 2020 Issue Published: 17 March 2020 Copyright & PermissionsCopyright © 2020 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Multidrug Resistance
Authors: I Pastan, M M Gottesman
Journal: Annual Review of Medicine (1991)

Laboratory investigations indicate that cancer cells can become simultaneously resistant to many different chemotherapeutic drugs that are natural products via the expression of an energy-dependent drug efflux pump. This multidrug transporter is a plasma membrane glycoprotein encoded in the human by the MDR1 gene. Recent clinical studies indicate that expression of the multidrug transporter plays a major role in the intrinsic and acquired resistance to chemotherapy of many human cancers. Strategies aimed at inactivating this drug efflux pump may have significant impact on the treatment of human cancer.
THE ADDRESS OF THE PRESIDENT.
Journal: JAMA (1902)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Management of prolonged motor seiqure activity in children
Authors: R. Calderon-Gonzalez
Journal: JAMA (1968)

Prolonged motor seizure activity was controlled with intravenously administered diazepam (5 to 10 mg) in 36 children ranging from one month to 12 years of age. Of the children, 10 had acute structural or metabolic cerebral disease or both, 12 had acute seizure disorder of undetermined origin, and the other 14 had old non-progressive cerebral disease. There were no serious complications secondary to this therapy.
RADIOACTIVE PHOSPHORUS AS A THERAPEUTIC AGENT
Authors: P. W. C.
Journal: Annals of Internal Medicine (1946)

Editorial1 October 1946RADIOACTIVE PHOSPHORUS AS A THERAPEUTIC AGENTP. W. C.P. W. C.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-25-4-742 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptRadioactive phosphorus has now been used therapeutically for several years, chiefly in the treatment of leukemia and polycythemia. Although the number of cases treated and the period of observation are still small, enough has been learned to warrant some tentative conclusions as to the value and limitations of this drug.When ordinary phosphorus (P31) is bombarded with deuterons (nuclei of heavy hydrogen) emitted at high speed by a cyclotron, an additional neutron is forced into the nucleus of some of the phosphorus atoms. This increases the mass of the atom (P32), which now contains 15 protons and 17 neutrons. The...1 LAWRENCESCOTTTUTTLE JHKGLW: Studies on leukemia with the aid of radioactive phosphorus, Internat. Clin., 1939, iii, 33. Google Scholar2 ERFTUTTLELAWRENCE LALWJH: Clinical studies with the aid of radiophosphorus. IV. The retention in blood, the excretion and the therapeutic effect of radiophosphorus on patients with leukemia, Ann. Int. Med., 1941, xv, 487. Google Scholar3 REINHARDMOOREBIERBAUMMOORE EHCVOSS: Radioactive phosphorus as a therapeutic agent. A review of the literature and analysis of the results of treatment of 155 patients with various blood dyscrasias, lymphomas, and other malignant neoplastic diseases, Jr. Lab. and Clin. Med., 1946, xxxi, 107. Google Scholar4 LAWRENCE JH: Nuclear physics and therapy: Preliminary report on a new method of treatment of leukemia and polycythemia, Radiology, 1940, xxxv, 51. CrossrefGoogle Scholar5 ERFLAWRENCE LAJH: Clinical studies with the aid of radiophosphorus. III. The absorption and distribution of radio-phosphorus in the blood of, its excretion by, and its therapeutic effect on, patients with polycythemia, Ann. Int. Med., 1941, xv, 276. Google Scholar6 ERFJONES LAHW: Radio-phosphorus—an agent for the satisfactory treatment of polycythemia and its associated manifestations; a report of a case of polycythemia secondary possibly to the Banti's syndrome, Ann. Int. Med., 1943, xix, 587. Google Scholar7 HALLWATKINSHARGRAVESGIFFIN BECHMMHZ: Radioactive phosphorus in the treatment of polycythemia vera. Results and hematologic complications, Am. Jr. Med. Sci., 1945, ccix, 712. CrossrefGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 October 1946Volume 25, Issue 4Page: 742-746KeywordsDrugsPhosphorusPolycythemia ePublished: 1 December 2008 Issue Published: 1 October 1946 PDF downloadLoading ...
Health Effects of Acid Aerosols on North American Children: Respiratory Symptoms
Authors: Douglas W. Dockery, Joan Cunningham, Andrew I. Damokosh, Lucas M. Neas, John D. Spengler, Petros Koutrakis, James H. Ware, Mark Raizenne, Frank E. Speizer
Journal: Environmental Health Perspectives (1996)

We examined the respiratory health effects of exposure to acidic air pollution among 13,369 white children 8 to 12 years old from 24 communities in the United States and Canada between 1988 and 1991. Each child's parent or guardian completed a questionnaire. Air quality and meteorology were measured in each community for a 1-year period. We used a two-stage logistic regression model to analyze the data, adjusting for the potential confounding effects of sex, history of allergies, parental asthma, parental education, and current smoking in the home. Children living in the community with the highest levels of particle strong acidity were significantly more likely [odds ratio (OR) = 1.66; 95% confidence interval (CI) 1.11-2.48] to report at least one episode of bronchitis in the past year compared to children living in the least-polluted community. Fine particulate sulfate was also associated with higher reporting of bronchitis (OR = 1.65; 95% CI 1.12-2.42). No other respiratory symptoms were significantly higher in association with any of the air pollutants of interest. No sensitive subgroups were identified. Reported bronchitis, but neither asthma, wheeze, cough, nor phlegm, were associated with levels of particle strong acidity for these children living in a nonurban environment.
Abstract 4832: Preclinical evaluation of neratinib plus T-DM1 in orthotopic PDX models of HER2-positive breast cancer brain metastases
Authors: Jing Ni, Yanzhi Wang, Irmina Diala, Sheheryar Kabraji, Rachel Freedman, Nancy Lin, Jean Zhao
Journal: Cancer Research (2019)

Abstract Up to half of patients with metastatic HER2-positive breast cancer will develop brain metastases. Breast cancer brain metastases (BCBM) are a major cause of morbidity and mortality, despite multimodal management including surgery, radiotherapy, and systemic therapies. Therefore, there is an urgent need to develop novel, efficacious therapies. Neratinib is an orally bioavailable, irreversible pan-HER tyrosine kinase inhibitor that is FDA-approved in the extended adjuvant treatment setting for HER2-positive, early breast cancer. Neratinib has only modest activity as a single agent in clinical trials of patients with HER2-positive brain metastases. Though the combination of neratinib and capecitabine results in CNS responses in up to half of patients, patients eventually develop drug resistance, and toxicities have been a concern-thus exploration of alternative neratinib combinations is of significant clinical interest. Ado-trastuzumab emtansine (T-DM1) is an antibody-drug conjugate with reported single-agent activity against HER2-positive BCBM. Here, we used HER2-positive orthotopic patient derived xenograft (PDX) models of BCBM to test if combining neratinib with T-DM1 could improve tumor response. PDX cells are labelled with luciferase to allow tumor growth measurement in vivo. We found that neratinib is able to reduce phosphorylated HER2 in an orthotopic PDX tumor derived from HER2-positive BCBM, indicating that neratinib can cross the BBB and inhibit HER2 activation in BCBM PDX tissues. However, in the HER2-positive DF-BM354 PDX model, single agent neratinib did not block orthotopic tumor growth compared to vehicle control as monitored by bioluminescence measurements. In contrast, combined treatment of neratinib with T-DM1 significantly reduced tumor growth compared to single agent treatment of neratinib or T-DM1 alone at earlier time points. At later time points, the combined treatment is comparable to T-DM1 alone. These data warrant further testing of neratinib alone or in combination with T-DM1 in additional BCBM PDX models to better understand drivers of resistance and susceptibility to HER2-inhibitors in HER2-positive BCBMs. Furthermore, they support the launch of a prospective clinical trial (NCT01494662) to test the efficacy and tolerability of T-DM1 in combination with neratinib in patients with progressive HER2-positive BCBM. Citation Format: Jing Ni, Yanzhi Wang, Irmina Diala, Sheheryar Kabraji, Rachel Freedman, Nancy Lin, Jean Zhao. Preclinical evaluation of neratinib plus T-DM1 in orthotopic PDX models of HER2-positive breast cancer brain metastases [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 4832.
What to do about dietary saturated fats?
Authors: C. Marwick
Journal: JAMA (1989)

MANY cholesterol-lowering recommendations suggest reducing dietary saturated fats and replacing them with unsaturated fats. But there is mounting concern that wholesale replacement of saturated with unsaturated fats may be too much of a good thing. So, is it time to revise current dietary recommendations to strike a balance among these fats? Not yet—at least as far as American Heart Association (AHA) guidelines are concerned—concluded participants in a Washington, DC, AHA meeting. The conclusion is strictly interim. "This is going to be evaluated over and over again," predicts the meeting's chair, Robert J. Nicolosi, MD, Department of Clinical Laboratory Sciences, University of Lowell (Mass). However, while warning against losing sight of the main message—lower the amount of saturated fats in the diet—he adds that a new issue is: What is the replacement for saturated fats? By some estimates, 15% of the calories in the US diet come from saturated fat. The
CUEEENT LITEEATUEE
Journal: British Journal of Dermatology (1936)

British Journal of DermatologyVolume 48, Issue 6 p. 324-329 CUEEENT LITEEATUEE First published: June 1936 https://doi.org/10.1111/j.1365-2133.1936.tb10352.xAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat Volume48, Issue6June 1936Pages 324-329 RelatedInformation
Public Forum on Informed Consent in Clinical Research Conducted in Emergency Circumstances
Journal: JAMA (1994)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Evaluation of a Possible Role for Antimutagens, Antiteratogens, and Anticarcinogens in Reducing Environmental Health Hazards
Authors: N. Nashed
Journal: Environmental Health Perspectives (1976)

The use of protective agents (e.g., sulfhydryl compounds, certain vitamins, amino acids, cations, and antibiotics) offers a novel and promising means of dealing with the ever increasing burden of environmental hazards facing man. Through the daily uptake of minimal doses as a prophylactic measure by the most endangered groups of the population or by direct mixing of the appropriate protective agent with the inducer (e.g., pesticides or anticancer drugs) it should be possible to reduce or prevent some of the most serious toxic side effects including those of a mutagenic, teratogenic or carcinogenic nature. Among some of the most outstanding protection examples cited are the antimutagenic, antiteratogenic and anticarcinogenic effects of L-cystein, and of some of the vitamins. However, in view of our limited understanding of protection mechanisms in this fairly new field of research and due to the toxic side effects of some of the protection agents themselves, a large-scale application of this approach cannot be recommended as yet. More research is urgently needed to study protection mechanisms in suitable standardized model systems and to develop safer and more efficient protective agents.
Gender and Risk of Autoimmune Diseases: Possible Role of Estrogenic Compounds
Authors: S. Ansar Ahmed, B. D. Hissong, D. Verthelyi, K. Donner, K. Becker, E. Karpuzoglu-Sahin
Journal: Environmental Health Perspectives (1999)

A striking common feature of many autoimmune diseases in humans and experimental animals, despite differences in pathology, is that females are highly susceptible to autoimmune conditions compared to males.In several animal models, estrogens promote, whereas androgens abrogate, B-cell-mediated autoimmune diseases.To understand mechanisms by which estrogens regulate autoimmunity, it is first necessary to decipher estrogen effects on the normal immune system.Estrogen treatment of nonautoimmune mice diminished lymphocyte numbers in both developmental and mature lymphoid organs.Estrogen dysregulated T-and B-cell balance by inducing selective T-cell hypoactivity and B-cell hyperactivity.Even though estrogen did not alter the relative percentages of splenic T-cell subsets, splenic lymphocytes had a reduced proliferative response to T-cell stimulants and were refractory to rescue from activation-induced apoptosis compared to cells from placebo-treated mice.In contrast, estrogen induced B-cell hyperactivity (promoted autoantibodies to double-stranded DNA and phospholipids, increased numbers of plasma cells, and increased autoantibody yield per B cell).Note that treatment of normal mice with estrogen can alter T-and B-cell regulation and overcome B-cell tolerance to result in autoimmunity in normal individuals.Could environmental estrogens promote some human autoimmune disorders?Is there a link between environmental estrogens and autoimmune disorders, especially since these disorders are reported possibly more frequently?These provocative questions warrant investigation.Our findings on immunomodulatory effects may serve as a benchmark to examine whether endocrine-disrupting chemicals will have similar immunologic effects.
Reply to Stanciu et al. and Weber et al.
Authors: Ian Gralnek
Journal: Endoscopy (2013)

On behalf of my co-authors, I would like to thank Stanciu et al. and Weber et al. for their letters to the Editor. The most efficient diagnostic algorithm for evaluation of acute upper gastrointestinal hemorrhage (UGIH) in the emergency department remains unclear [1]. Most patients who present with signs of acute UGIH are often put through uncomfortable diagnostic tests (e. g. nasogastric aspiration) that have questionable value. Moreover, most patients, even when they are considered to be at low risk for poor outcomes, are admitted to the hospital for reasons that are multifactorial. We believe that more efficient tools (e. g. video capsule endoscopy [VCE]) are needed in this clinical scenario, especially for those patients who are considered to be clinically at low risk and for whom hospital admission could be avoided.
Insig: a significant integrator of nutrient and hormonal signals
Authors: A. D. Attie
Journal: Journal of Clinical Investigation (2004)

Lipogenesis is regulated by sterols and by insulin through the regulated expression and activation of the sterol regulatory element–binding proteins (SREBPs). A new study shows one way in which sterol and insulin regulation can be decoupled. In transgenic mice overexpressing a protein that regulates SREBP activation, lipogenesis is more sensitive to cholesterol and less sensitive to insulin.
NAVY DAY
Journal: JAMA (1923)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal